Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ASCO 2026

American Society of Clinical Oncology

May 29 - June 02, 2026

  1. All
  2. Durvalumab
  3. Volrustomig
  4. AZD3470
  5. Savolitinib
  6. Camizestrant
  7. AZD9750
  8. Dato-Dxd
  9. T-DXd
  10. Sonesitatug vedotin
  11. Puxitatug samrotecan
  12. Rilvegostomig
  13. Trastuzumab deruxtecan

PDF

Durvalumab (D) in combination with BCG induction and maintenance (I + M) therapy for BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC

PPT

Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.

PPT

Impact of Neoadjuvant Durvalumab on Tumor Microenvironment Features and Their Association with Event-free Survival in Patients with Resectable NSCLC (R-NSCLC) from the Phase 3 AEGEAN Trial

PDF

Efficacy of durvalumab and safety by treatment period in MATTERHORN: a randomized, Phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in resectable gastric / gastroesophageal junction cancer

PPT

Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants with unresectable embolization-eligible hepatocellular carcinoma (eeHCC)

PDF

Volrustomig monotherapy for recurrent/metastatic HNSCC: substudy 2 of the eVOLVE-02 phase 2 study

PPT

A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA)

PDF

Comprehensive epigenomic profiling of plasma for non-invasive detection of MET activation to uncover MET-associated biology in patients with EGFR-mutated advanced NSCLC and progression on osimertinib

PPT

A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinomas

PDF

Camizestrant plus ribociclib in hormone receptor-positive/HER2-negative advanced breast cancer: The phase II CADILLAC trial

PDF

Prognostic Value of ESR1 Mutation Status in Metastatic Breast Cancer Patients Receiving Second-Line Therapy: A Real-World Evidence Study

PDF

First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial

PDF

Phase I/II study to evaluate AZD9750, a novel androgen receptor proteolysis-targeting chimera, alone and in combination with other anticancer agents in patients with metastatic prostate cancer (ANDROMEDA)

PDF

TROPION-Urothelial03: A Phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab

PDF

First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study

PDF

A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P)

PDF

Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP)

PDF

Impact of adherence to interstitial lung disease (ILD)/pneumonitis toxicity management guidelines (TMGs) on ILD/pneumonitis outcomes: a retrospective analysis of patients (pts) treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Breast06 (DB-06)

PDF

First-line trastuzumab deruxtecan -based regimens in advanced HER2-expressing gastric cancer , gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma : safety results from DESTINY-Gastric03 Part 2 arms D and F, and Part 4

PDF

Additional health-related quality of life analysis from DESTINY-Gastric04, a randomized phase 3 study of trastuzumab deruxtecan vs ramucirumab + paclitaxel in patients with HER2-positive unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma

PDF

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2-low gastroesophageal adenocarcinoma (EPOC2203)

PDF

Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2-positive gastric cancer: exploratory analyses from the phase 2 EPOC2003 study

PDF

Trastuzumab deruxtecan for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 Part 1 primary analysis

PDF

A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 immunohistochemistry 3+ solid tumors: DESTINY-PanTumor04

PDF

Topoisomerase 1 and DNA damage pharmacodynamic responses and proof of mechanism of trastuzumab deruxtecan in HER2-expressing advanced solid tumors

PDF

HER2-independent antitumor activity and pharmacodynamic response to trastuzumab deruxtecan in patients with advanced solid tumors

PDF

Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): final analysis from DESTINY-Breast07.

PDF

Sonesitatug vedotin (Sone-Ve) monotherapy in patients with claudin 18.2-positive advanced or metastatic gastric or gastroesophageal junction cancers: Initial data from CLARITY-PanTumor01

PDF

Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study

PDF

Safety and efficacy of puxitatug samrotecan in patients with biliary tract cancer : a first-in-human Phase 1/2a study (BLUESTAR)

PDF

Trial in progress: puxitatug samrotecan (AZD8205) vs chemotherapy in patients with B7-H4-selected advanced/metastatic endometrial cancer: the Phase 3 randomized Bluestar Endometrial01 (BE01)/GOG-3110/ENGOT-EN28 trial

PDF

ARTEMIDE-Biliary02: a global, phase 3 study of rilvegostomig or durvalumab in combination with chemotherapy as first-line (1L) treatment for advanced biliary tract cancer (BTC)

PDF

First-line rilvegostomig (R) + chemotherapy (CTx) in advanced biliary tract cancer (BTC): Updated analysis of GEMINI-Hepatobiliary substudy 2 Cohort A

PDF

Trastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients (pts) with human epidermal growth factor receptor 2 (HER2)-expressing ovarian cancer (OC): Results from the DESTINY-Ovarian01 (DO-01/ENGOT-ov89/GOG-3112/APGOT-OV13) safety run-in (SRI)

PDF

Durvalumab (D) in combination with BCG induction and maintenance (I + M) therapy for BCG-naive, high-risk non-muscle-invasive bladder cancer (NMIBC): 5-year overall survival (OS) analysis and patient-reported outcomes (PROs) from POTOMAC

PPT

Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.

PPT

Impact of Neoadjuvant Durvalumab on Tumor Microenvironment Features and Their Association with Event-free Survival in Patients with Resectable NSCLC (R-NSCLC) from the Phase 3 AEGEAN Trial

PDF

Efficacy of durvalumab and safety by treatment period in MATTERHORN: a randomized, Phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in resectable gastric / gastroesophageal junction cancer

PPT

Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants with unresectable embolization-eligible hepatocellular carcinoma (eeHCC)

PDF

Volrustomig monotherapy for recurrent/metastatic HNSCC: substudy 2 of the eVOLVE-02 phase 2 study

PPT

A phase 1 study of the PRMT5 inhibitor AZD3470 in patients with relapsed/refractory classic Hodgkin lymphoma (PRIMAVERA)

PDF

Comprehensive epigenomic profiling of plasma for non-invasive detection of MET activation to uncover MET-associated biology in patients with EGFR-mutated advanced NSCLC and progression on osimertinib

PPT

A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinomas

PDF

Camizestrant plus ribociclib in hormone receptor-positive/HER2-negative advanced breast cancer: The phase II CADILLAC trial

PDF

Prognostic Value of ESR1 Mutation Status in Metastatic Breast Cancer Patients Receiving Second-Line Therapy: A Real-World Evidence Study

PDF

First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial

PDF

Phase I/II study to evaluate AZD9750, a novel androgen receptor proteolysis-targeting chimera, alone and in combination with other anticancer agents in patients with metastatic prostate cancer (ANDROMEDA)

PDF

TROPION-Urothelial03: A Phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab

PDF

First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study

PDF

A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P)

PDF

Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): final analysis from DESTINY-Breast07.

PDF

Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP)

PDF

Impact of adherence to interstitial lung disease (ILD)/pneumonitis toxicity management guidelines (TMGs) on ILD/pneumonitis outcomes: a retrospective analysis of patients (pts) treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Breast06 (DB-06)

PDF

First-line trastuzumab deruxtecan -based regimens in advanced HER2-expressing gastric cancer , gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma : safety results from DESTINY-Gastric03 Part 2 arms D and F, and Part 4

PDF

Additional health-related quality of life analysis from DESTINY-Gastric04, a randomized phase 3 study of trastuzumab deruxtecan vs ramucirumab + paclitaxel in patients with HER2-positive unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma

PDF

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2-low gastroesophageal adenocarcinoma (EPOC2203)

PDF

Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2-positive gastric cancer: exploratory analyses from the phase 2 EPOC2003 study

PDF

Trastuzumab deruxtecan for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 Part 1 primary analysis

PDF

A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 immunohistochemistry 3+ solid tumors: DESTINY-PanTumor04

PDF

Topoisomerase 1 and DNA damage pharmacodynamic responses and proof of mechanism of trastuzumab deruxtecan in HER2-expressing advanced solid tumors

PDF

HER2-independent antitumor activity and pharmacodynamic response to trastuzumab deruxtecan in patients with advanced solid tumors

PDF

Sonesitatug vedotin (Sone-Ve) monotherapy in patients with claudin 18.2-positive advanced or metastatic gastric or gastroesophageal junction cancers: Initial data from CLARITY-PanTumor01

PDF

Updated safety and efficacy of puxitatug samrotecan (Puxi-Sam, AZD8205) in patients (pts) with endometrial cancer (EC) or ovarian cancer (OC): Phase 1/2a BLUESTAR study

PDF

Safety and efficacy of puxitatug samrotecan in patients with biliary tract cancer : a first-in-human Phase 1/2a study (BLUESTAR)

PDF

Trial in progress: puxitatug samrotecan (AZD8205) vs chemotherapy in patients with B7-H4-selected advanced/metastatic endometrial cancer: the Phase 3 randomized Bluestar Endometrial01 (BE01)/GOG-3110/ENGOT-EN28 trial

PDF

ARTEMIDE-Biliary02: a global, phase 3 study of rilvegostomig or durvalumab in combination with chemotherapy as first-line (1L) treatment for advanced biliary tract cancer (BTC)

PDF

First-line rilvegostomig (R) + chemotherapy (CTx) in advanced biliary tract cancer (BTC): Updated analysis of GEMINI-Hepatobiliary substudy 2 Cohort A

PDF

Trastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients (pts) with human epidermal growth factor receptor 2 (HER2)-expressing ovarian cancer (OC): Results from the DESTINY-Ovarian01 (DO-01/ENGOT-ov89/GOG-3112/APGOT-OV13) safety run-in (SRI)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States